Could stem cell therapy for osteoporosis one day help the skeleton rebuild itself? That’s the question behind a small but striking new study, and it’s the focus of this second article in our Better Bones Innovation Watch series, where emerging science meets timeless biological wisdom. (Our first Innovation Watch looked at the Osentia fingernail test and bone quality vs. bone density.)
For decades, discussions about osteoporosis have centered on a few nutrients like calcium and vitamin D and on bone drugs designed to slow bone loss and/or stimulate new bone formation. While these treatments have a place, they represent only one part of a much larger story.
The science of bone health is evolving rapidly. Around the world, researchers are developing innovative technologies, exploring new biological pathways, and revisiting wisdom-driven observations from traditional healing systems. Many of these ideas encourage us to think beyond bone mineral density and bone drugs, and to appreciate the remarkable intelligence and interconnectedness of the entire human body.
In this series, we’ll explore promising innovations with both curiosity and scientific rigor. Some may eventually transform clinical practice; others may not withstand the test of further research. Our goal is neither to promote nor dismiss new ideas prematurely, but to evaluate them thoughtfully, objectively, and always with your long-term bone health in mind.
Key takeaways
- A Phase 1 trial published September 11, 2026 in Cell gave 10 women with advanced osteoporosis a single infusion of their own modified bone-marrow stem/stromal cells (MSCs).
- Fragility fractures reportedly fell from roughly one every one to two years to closer to one per decade, and volumetric bone density increased.
- There was no control group, most women were also on osteoporosis medication, and researchers did not confirm the cells reached bone, so the study cannot show the therapy prevented fractures.
- The treatment appeared safe in this small group, but it is experimental and is not the same as commercially advertised “stem cell” clinics.
Could cell therapy help rebuild osteoporotic bone? A remarkable early study needs a closer look
September 2026 â Ten women with advanced osteoporosis received a single infusion of specially modified cells taken from their own bone marrow. What happened afterward has attracted considerable attention.
Before treatment, the women had been experiencing fragility fractures roughly every one to two years, on average. After receiving the experimental cell therapy, their fractures reportedly fell to a rate closer to one per decade.
The results, published September 11 in Cell, are intriguing enough to warrant serious attention. But this was a Phase 1 trial involving only 10 women, with no untreated control group. Most participants were also taking conventional osteoporosis medications.
So while this may be an exciting glimpse at a completely different way of approaching osteoporosis, it is far too early to know whether the treatment actually prevents fractures.
What makes this mesenchymal stem cell therapy different?
The experimental therapy involves mesenchymal stem/stromal cells, or MSCs. These cells are found in bone marrow and have the ability to differentiate into several cell types, including bone-forming osteoblasts.
That makes MSCs interesting candidates for regenerative bone therapy. There has been a major obstacle, however. When MSCs are simply infused into the bloodstream, they generally do not efficiently travel into bone.
Researchers led clinically by José Moraleda at the University of Murcia in Spain, working with regenerative-medicine researcher Robert Sackstein and colleagues, tried to solve that problem by modifying the outside surface of the cells. They added fucose, a naturally occurring sugar, to the cells through a process called exofucosylation.
The modification produces a cell-surface structure that improves interactions between the cells and blood-vessel walls. In theory, this allows circulating MSCs to slow down, adhere to blood vessels and ultimately enter bone marrow more effectively.
Earlier animal research suggested this could help direct the cells toward bone. Now researchers have tried the approach in people.
How was the treatment given?
Researchers enrolled 10 women with advanced osteoporosis and a history of fractures. Each woman’s own bone marrow was collected.
Mesenchymal stromal cells were then isolated and expanded in the laboratory for approximately a month. Before being returned to the participant, the cells underwent the fucosylation process designed to improve their ability to reach bone. The women then received a single intravenous infusion of their modified cells.
The first four women received 2 million cells per kilogram of body weight, while the remaining six received 5 million cells per kilogram.
This was not an off-the-shelf stem-cell injection. It was an individualized cell-manufacturing procedure conducted under controlled research conditions.
What happened to their fractures?
This is the finding generating the headlines.
According to the report in Nature, before treatment the participants experienced fractures of the spine, hip, arms and other bones approximately every one or two years, on average. After treatment, low-impact fractures occurred at a rate closer to one per decade.
The published Cell paper reports reduced fragility-fracture incidence following the single infusion and also reports increases in volumetric bone mineral density and changes in bone-metabolism biomarkers consistent with an osteoregenerative effect.
Those are certainly encouraging findings. But they require some important context.
Why we cannot say the treatment prevented those fractures
There were only 10 participants. More importantly, there was no control group. Researchers compared what happened to the women after treatment with what had happened to the same women before treatment.
That type of comparison can generate an important signal, particularly in an early safety study, but it cannot reliably establish cause and effect.
People who have experienced several fractures within a relatively short period may naturally experience fewer during a subsequent period. Statisticians call this regression to the mean.
There is another major complication. Most of the women were taking conventional osteoporosis medications before and during the study. That means researchers cannot cleanly separate any benefit of the cell treatment from the effects of those medications.
Nature specifically identified the small sample, lack of a control group and concurrent osteoporosis treatment as major reasons for caution in interpreting the dramatic fracture findings.
Did the cells actually reach their bones?
Surprisingly, researchers don’t yet know for certain. The entire premise behind the treatment is that adding fucose helps MSCs travel into bone more effectively.
Previous laboratory and animal research supports that biological mechanism. But researchers did not directly track the infused cells inside these women.
So although changes in bone density, fracture incidence and bone-metabolism markers are consistent with a possible regenerative effect, this study did not demonstrate directly that the modified cells reached the participants’ bones and produced those changes. That is an important unanswered question for future studies.
Is stem cell therapy for osteoporosis safe?
Safety was the primary purpose of this early trial. The Cell paper identifies intravenous infusion of these exofucosylated autologous MSCs as safe in this small study. That is encouraging.
But safety in 10 carefully selected participants is very different from establishing safety in hundreds or thousands of people. Rare complications may not appear until substantially larger numbers of people have received a treatment. This study therefore provides an important first piece of safety information, rather than a definitive safety profile.
Why this research is still exciting
With all those cautions, there is something genuinely interesting happening here. Much of osteoporosis treatment has traditionally focused on altering the balance between bone breakdown and bone formation.
This experimental approach asks a somewhat different question:
Could we help restore the skeleton’s own regenerative capacity by delivering bone-forming progenitor cells where they are needed?
The Cell investigators describe the changes in bone metabolism as consistent with an osteoregenerative effect. If that concept survives larger randomized trials, it could represent an intriguing new direction in osteoporosis research. But that “if” is enormously important.
Dr. Brown’s take: Regenerating bone is an exciting goal, but 10 people cannot give us the answer
This research caught my attention.
For decades, I have looked at bone as living, dynamic tissue with an extraordinary capacity to continually break down, rebuild and adapt. So the concept behind this study is fascinating.
Rather than looking only at how we can slow bone breakdown, these researchers are asking whether we can improve the body’s ability to regenerate bone by directing regenerative cells back to the skeleton. That is a very interesting question.
And the reduction in fractures reported among these 10 women certainly makes me want to see more research. But it does not yet convince me that the treatment caused that reduction.
Extraordinary results require good controls
When we hear that fractures went from approximately one every year or two to roughly one every decade, it is natural to become excited. I am excited by the possibility too.
But this is exactly when we need to look carefully at how the study was designed. There were only 10 women. There was no comparison group. And most of these women were also using conventional osteoporosis medications.
That means we cannot know how much of the improvement came from the cell therapy, how much may have come from other treatment, and how much might represent the natural variation in fracture occurrence over time.
Those questions don’t make the results meaningless. They tell us what the next experiment needs to answer.
What I would like to see now is a larger randomized controlled trial that follows people carefully over several years and compares fracture outcomes, bone density, bone quality and markers of bone remodeling. If the dramatic fracture reduction persists under those conditions, then we will have something truly important to talk about.
Bone regeneration is bigger than any single therapy
There is another reason I find this study interesting. The entire premise is based on the fact that our skeleton is capable of regeneration.
Sometimes we talk about osteoporosis as though bone were an inert structure that simply becomes thinner with age. It isn’t.
Bone is metabolically active tissue. Old or damaged bone is continually removed and new bone is continually formed.
Our nutrition, hormonal environment, muscle activity, mechanical loading, inflammation, overall health and many other factors influence that remodeling process.
A sophisticated cell therapy and good nutrition and exercise obviously operate on very different levels. I would never suggest that lifestyle changes reproduce what researchers are attempting with this experimental procedure.
But they share an important biological principle:
Bone is responsive tissue.
That is an encouraging message for anyone working to improve their bone health.
What should someone with severe osteoporosis do with this information?
For now, I would treat this as exciting research to watch, not as a treatment option to pursue. This therapy requires bone-marrow collection, laboratory expansion and modification of an individual’s cells, and specialized infusion. It remains experimental.
I would also be very cautious about assuming that commercially advertised “stem cell” treatments for osteoporosis are equivalent to what was studied here. They are not necessarily the same thing at all.
For someone experiencing repeated fractures despite treatment, the important step today is still to work with an experienced healthcare professional and conduct a thorough evaluation.
I would want to understand the individual’s fracture history, bone density and bone quality, bone turnover, nutritional status, hormonal and metabolic factors, medications, strength, balance, fall risk, and potential secondary causes of osteoporosis. For some people, osteoporosis medication will also be an important part of reducing fracture risk.
Meanwhile, researchers can answer the fascinating question raised by this trial:
Can directing a person’s own regenerative cells back to bone actually help rebuild a fragile skeleton and prevent fractures?
These first 10 women give us a reason to investigate that question much more seriously. They do not yet give us the answer.
The Better Bones bottom line
This is one of the more intriguing early-stage osteoporosis studies we have seen because researchers are exploring a genuinely different therapeutic strategy: modifying a person’s own bone-marrow stromal cells so they can better home to bone and potentially support regeneration.
The preliminary findings are encouraging. The Cell paper reports reduced fragility-fracture incidence, increased volumetric bone mineral density and changes in bone-metabolism markers consistent with an osteoregenerative effect after a single infusion.
But the study included only 10 women, had no control group, and included participants who were also receiving conventional osteoporosis treatments. Researchers also did not directly establish that the infused cells reached the women’s bones.
So the appropriate conclusion is not that stem-cell therapy has been shown to prevent osteoporosis fractures. It is that researchers have found a promising signal worth testing rigorously.
If a larger randomized trial can reproduce these results â particularly the reduction in fragility fractures â this could become a very important area of osteoporosis research.
Until then, those living with osteoporosis should continue focusing on what can be evaluated and acted upon today: understanding the causes of their bone loss, reducing fall and fracture risk, providing the nutrients and exercise necessary to support bone, and working with their healthcare team to determine whether medication or other treatment is appropriate.
Frequently asked questions about stem cell therapy for osteoporosis
Can stem cells rebuild bone in osteoporosis?
Possibly, but it has not been proven. In a 10-woman Phase 1 trial published in Cell in September 2026, a single infusion of each woman’s own modified bone-marrow MSCs was followed by fewer fractures, higher volumetric bone density and bone-marker changes consistent with new bone formation. Without a control group, the study cannot show the cells caused those changes.
What is exofucosylation?
Exofucosylation adds fucose, a naturally occurring sugar, to the outer surface of cells. In this study it was used to help infused mesenchymal stem/stromal cells stick to blood-vessel walls and move into bone marrow, rather than circulating past it.
Is stem cell therapy an approved osteoporosis treatment?
No. The therapy studied here is experimental and was given only under controlled research conditions. Commercially advertised “stem cell” treatments for osteoporosis are not necessarily the same thing and should be approached with caution.
What would prove whether this therapy works?
A larger randomized controlled trial that compares treated and untreated people over several years, tracking fracture outcomes, bone density, bone quality and bone-remodeling markers.
Primary sources
- Moraleda JM, Linares LF, GarcĂa-Bernal D, et al. “Glycocalyx-edited mesenchymal stem/stromal cell therapy in advanced osteoporosis.” Cell. Published online September 11, 2026. DOI: 10.1016/j.cell.2026.08.017.
- Dolgin E. “Osteoporosis affects millions: could modified cells rebuild their bones?” Nature. September 11, 2026.
This article is educational and is not medical advice. The cell therapy described here is experimental and is not an established treatment for osteoporosis. Do not start, stop or change osteoporosis treatment based on this or any other news report. Discuss treatment decisions with the healthcare professional managing your bone health.
